Offer - Urjas Oil for just ₹ 1 X
Bispec 5 Tablet (15) is a commercial drug that is prescribed in the form of Tablet. Primarily, it is used for the treatment of Urinary Incontinence. Secondary and off-label uses of Bispec 5 Tablet (15) have also been mentioned below.
The correct dosage of Bispec 5 Tablet (15) depends on the patient's age, gender, and medical history. The condition it has been prescribed for, and the route of administration also determine the right dosage. Refer to the dosage section for a detailed discussion.
Some other side effects of Bispec 5 Tablet (15) have been listed ahead. Such side effects of Bispec 5 Tablet (15) normally do not last long and go away once the treatment is completed. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of Bispec 5 Tablet (15) is Moderate for pregnant women and Moderate for women who are breastfeeding. It is important to know if Bispec 5 Tablet (15) has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Bispec 5 Tablet (15) related warnings section.
Bispec 5 Tablet (15) is not recommended if you suffer from certain medical conditions as it can have adverse effects. Kidney Disease, Liver Disease are examples of such conditions. Some other conditions that can be affected by Bispec 5 Tablet (15) are listed in the contraindications section below.
Drug interactions for Bispec 5 Tablet (15) have been reported in the medical literature. See below for a complete list.
In addition to the above precautions for Bispec 5 Tablet (15), it is important to know that it is not safe while driving, and is not habit-forming.
Bispec 5 Tablet (15) is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Bispec 5 Tablet (15) safe for pregnant women?
Bispec can cause unwanted side effects in pregnant women. If you experience any side effects, stop taking Bispec right away. Take your doctor's advice before taking it again.
Is the use of Bispec 5 Tablet (15) safe during breastfeeding?
If you are breastfeeding, you may experience some harmful effects of Bispec. In case you experience any of these, discontinue its use until you consult your doctor.
What is the effect of Bispec 5 Tablet (15) on the Kidneys?
Bispec rarely harms the kidneys.
What is the effect of Bispec 5 Tablet (15) on the Liver?
Bispec may have mild side effects on the liver. Most people will never see any effect on the liver.
What is the effect of Bispec 5 Tablet (15) on the Heart?
Bispec is rarely harmful for the heart.
If you are suffering from any of the following diseases, you should not take Bispec 5 Tablet (15) unless your doctor advises you to do so -
Is this Bispec 5 Tablet (15) habit forming or addictive?
Bispec 5 Tablet (15) is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
No, you should not drive or operate heavy machinery after taking Bispec 5 Tablet (15) as you may feel sleepy.
Is it safe?
Yes, but take Bispec 5 Tablet (15) only as per medical advice.
Is it able to treat mental disorders?
There is no benefit of taking Bispec 5 Tablet (15) for mental disorders.
Interaction between Food and Bispec 5 Tablet (15)
Taking Bispec 5 Tablet (15) with food does not harm your health.
Interaction between Alcohol and Bispec 5 Tablet (15)
Taking Bispec 5 Tablet (15) with alcohol can have severely harmful effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; VESIcare® (solifenacin succinate)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1151